The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.c

Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

A characteristic complication of the drug, although a parasitic etiology needs be ruled out

Publications

Haroon M, Harney S

A case of severe pulmonary infiltration with eosinophilia (PIE) syndrome induced by sulphasalazine.

International journal of rheumatic diseases. 2012;15(6):e150-2

Park JE, Hwangbo Y, Chang R, Chang YW, Jang JY, Kim BH, Dong SH, Kim HJ

[Mesalazine-induced eosinophilic pneumonia in a patient with Crohn's disease].

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi. 2009;53(2):116-20

Parry SD, Barbatzas C, Peel ET, Barton JR

Sulphasalazine and lung toxicity.

The European respiratory journal. 2002;19(4):756-64

Wang KK, Bowyer BA, Fleming CR, Schroeder KW

Pulmonary infiltrates and eosinophilia associated with sulfasalazine.

Mayo Clinic proceedings. 1984;59(5):343-6

Berliner S, Neeman A, Shoenfeld Y, Eldar M, Rousso I, Kadish U, Pinkhas J

Salazopyrin-induced eosinophilic pneumonia.

Respiration; international review of thoracic diseases. 1980;39(2):119-20

Jones GR, Malone DN

Sulphasalazine induced lung disease.

Thorax. 1972;27(6):713-7

Eastwood M

Letter: Sulphasalazine-induced lung disease.

Lancet (London, England). 1974;2(7881):659-60

Scherpenisse J, van der Valk PD, van den Bosch JM, van Hees PA, Nadorp JH

Olsalazine as an alternative therapy in a patient with sulfasalazine-induced eosinophilic pneumonia.

Journal of clinical gastroenterology. 1988;10(2):218-20

Jordan A, Cowan RE

Reversible pulmonary disease and eosinophilia associated with sulphasalazine.

Journal of the Royal Society of Medicine. 1988;81(4):233-5

Cazzadori A, Braggio P, Bontempini L

Salazopyrin-induced eosinophilic pneumonia.

Respiration; international review of thoracic diseases. 1985;47(2):158-60

Assouline PS, Diot P, Janvoie B, Lemarié E, Hamon B, Asquier E, Lavandier M

[Pneumopathy due to sulfasalazopyrine. A case with a challenge test].

Revue des maladies respiratoires. 1991;8(2):233-6

Yamakado S, Yoshida Y, Yamada T, Kishida T, Kobayashi M, Nomura T

Pulmonary infiltration and eosinophilia associated with sulfasalazine therapy for ulcerative colitis: a case report and review of literature.

Internal medicine (Tokyo, Japan). 1992;31(1):108-13

Constantinidis KA

Letter: Eosinophilic pneumonia: an unusual side effect of therapy with salicylazosulfapyridine.

Chest. 1976;70(2):315-6